Recent advances in basic science methodology to evaluate opioid safety profiles and to understand opioid activities

Aliza T. Ehrlich 1, Emmanuel Darcq 2,3*

1 Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA
2 Department of Psychiatry, Douglas Research Center, McGill University, Montréal, Canada
3 INSERM U1114, UNISTRA University of Strasbourg, Strasbourg, France

Abstract

Opioids are powerful drugs used by humans for centuries to relieve pain and are still frequently used as pain treatment in current clinical practice. Medicinal opioids primarily target the mu opioid receptor (MOR), and MOR activation produces unmatched pain-alleviating properties, as well as side effects such as strong rewarding effects, and thus abuse potential, and respiratory depression contributing to death during overdose. Therefore, the ultimate goal is to create opioid pain-relievers with reduced respiratory depression and thus fewer chances of lethality. Efforts are also underway to reduce the euphoric effects of opioids and avoid abuse liability. In this review, recent advances in basic science methodology used to understand MOR pharmacology and activities will be summarized. The focus of the review will be to describe current technological advances that enable the study of opioid analgesics from subcellular mechanisms to mesoscale network responses. These advances in understanding MOR physiological responses will help to improve knowledge and future design of opioid analgesics.

Keywords

GPCR, Network, Signaling, Biased, fMRI, Circuitry, Mu opioid receptor, MOR

Peer Review

The peer reviewers who approve this article are:

1. **Laura M Bohn**, Departments of Molecular Medicine and Neuroscience, the Scripps Research Institute, Florida, USA
   **Competing interests:** No competing interests were disclosed.

2. **Christoph Stein**, Department of Experimental Anaesthesiology, Charité Universitätsmedizin, Berlin, Germany
   **Competing interests:** Dr Stein is listed as inventor on US patent 14/239,461. This patent is owned by Charité Universitätsmedizin Berlin.
*Corresponding author: Emmanuel Darcq (edarcq@unistra.fr)

Competing interests: The authors declare that they have no competing interests.

Grant information: This work was supported by a NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation (27303, ATE) and by the University of Strasbourg initiative of Excellence (ED).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2021 Darcq E et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Ehrlich AT and Darcq E. Recent advances in basic science methodology to evaluate opioid safety profiles and to understand opioid activities. Faculty Reviews 2021 10(15). https://doi.org/10.12703/r/10-15

Published: 19 Feb 2021, Faculty Reviews 10(15) https://doi.org/10.12703/r/10-15
Introduction

The mu opioid receptor (MOR) is the primary molecular target for medicinal opioids\(^1\). MOR activation mediates the unparalleled analgesic properties of opioids, as well as several side effects (constipation, respiratory depression, and abuse liability). Unfortunately, the prescription rate of opioids has increased dramatically in recent years, and a portion of patients with opioid prescriptions develop an opioid use disorder due in part to their strong euphoric effect. Prescribed opioids are now at the center of a rising “opioid epidemic” in North America\(^6,7\) and in Europe\(^8,9\), increasing the risk of deaths by overdose. Improving our understanding of how MORs operate at the subcellular level to impact physiology is critical for the development of safer MOR analgesics with more precise painkilling effects.

MORs are G-protein-coupled receptors (GPCRs) that localize to cellular membranes, where they are activated by endogenous peptides or exogenous ligands to induce signaling responses that inhibit neuronal excitability (Figure 1). When activated by agonists, MORs bind to G\(\alpha\)/o proteins to induce the exchange of GDP for GTP, which in turn releases G\(\beta\)\(\gamma\) subunits and inhibits adenylyl cyclase from producing cyclic adenosine monophosphate (cAMP). This sequence of events contributes to e.g. altering gene expression\(^10\), antinociception\(^11\), and the development of opiate tolerance, dependence, and withdrawal\(^12\). Opioid receptor activation releases G\(\beta\)\(\gamma\) subunits, which bind and inhibit L-type voltage-gated calcium channels, which in turn inhibits neurotransmitter release and reduces neurotransmission of pain signals\(^11\). MOR also induces G\(\beta\)\(\gamma\) activation of G-protein-coupled inwardly rectifying potassium (GIRK) channels, which allows potassium to flow out of the neuron, resulting in a negative charge or hyperpolarization of the cell and decreased neurotransmission in regions such as ventral tegmental area dopaminergic neurons\(^13–15\). To remove the receptor from the plasma membrane, GPCR kinases (GRKs) phosphorylate the receptor\(^16\) and recruited \(\beta\)-arrestin moves the receptor into clathrin-coated pits, where dynamin-dependent endocytosis of the receptors ensues\(^17,19\). The endosome then transports MORs\(^19\) to be recycled for another round of activation\(^20\) or to the degradation pathway via lysosomes\(^21\).

An essential component for understanding opioid analgesia is improving our fundamental knowledge of the cellular (microscale) and circuit (mesoscale) levels of organization of opioid receptors and their ligands\(^22\). A main question in the field is whether opioids can produce an analgesic effect without dangerous side effects such as respiratory depression and euphoria. Some evidence already supports this possibility: for example, efforts to produce safer opioids include bypassing the central nervous system altogether. The generation of peripherally limited ligands avoids addictive properties of opioids, such as reward\(^3\). A pH-sensitive ligand was shown to target peripheral MORs in inflamed tissues, where it produced inflammatory-restricted analgesia without central or intestinal side effects\(^13,24\). These and other current strategies to design safer opioids have been comprehensively discussed elsewhere\(^3,25–29\).

This review concentrates on describing some of the recent advances in basic science methodology that enable the study

---

**Figure 1. Current view of mu opioid receptor (MOR) trafficking, signaling, and cellular response.** 1. MORs are classically localized to the plasma membrane. 2. Ligand activation (i.e. morphine binding to the orthosteric site) induces conformational changes in the receptor so that G\(\alpha\)/o proteins can bind and release G\(\beta\)\(\gamma\) subunits, which bind to ion channels such as G-protein-coupled inwardly rectifying potassium (GIRK) channels. 3. G\(\alpha\)/o proteins inhibit transmembrane adenylyl cyclase-mediated cAMP production. 4. G-protein-coupled receptor kinases (GRKs) are recruited to phosphorylate MORs. 5. Adaptor proteins, \(\beta\)-arrestins (\(\beta\)-arr), recognize and bind to the phosphorylated receptor. 6. MORs are sorted into clathrin-coated pits, which are dynamin dependent. 7. Endosome vesicles containing MORs pinch off from the membrane, clearing receptors from the cell surface; however, receptors may continue to signal in endosomes, i.e. be sent to degradation in the lysosome, or ii. be recycled to the membrane for another round of signaling. 8. Current views also hold that MORs can be activated and signal from internal compartments like the Golgi, if ligands are cell permeable like alkaloids (i.e. morphine)\(^20,29\).
of opioid analgesics from microscale to mesoscale network responses. Classical methods employed to study the cellular mechanisms engaged by the opioid system such as electrophysiology, in situ hybridization, and immunohistochemistry are increasingly combined with new techniques (see Table 1) like optogenetic or chemogenetic tools and knock-in (KI) animals and are leading to new insights about the cellular regulation of opioids. Furthermore, new methods in brain imaging are also helping to identify the contribution of MOR activation to physiological effects by mapping the whole activity and synchrony of brain areas. Specifically, magnetic resonance imaging (MRI) is a unique and most informative approach to non-invasively investigate brain anatomy and connectivity of the entire brain in humans and animals. Whole-brain MRI has now been developed in animals to address and follow up, in a longitudinal manner, brain anatomy, functional and structural connectivity patterns, and neurochemistry profiles. Some of these approaches may have translational potential to be tested in the clinic and may reveal biological markers, should they correspond to biological parameters that influence or predict the incidence of a disease. Indeed, MRI is an unparalleled non-invasive and versatile method, which makes it feasible to capture the longitudinal effects during different phases of a disease and thus has strong translatability from pre-clinical to human research. Recently, a pharmacological-MRI approach was used to understand whole-brain responses to opioids in living animals, suggesting that MRI approaches may soon prove useful for opioid drug development. There are several key methodologies that are actively working to delineate opioid responses at cellular and system levels as well as map and characterize opioid sites of action to improve our understanding of opioids and guide drug development.

Selected recent methodologies will be summarized in this review.

**Investigating ligand-directed functional selectivity at MORs**

At the microscale, opioid responses begin with ligand-binding the receptor to initiate signaling cascades. There are several well-characterized pathways for receptor regulation. Early observations of agonist selective regulation of MOR activity motivated the idea now known as “functional selectivity” or “biased agonism”, suggesting that two distinct agonists which activate the same receptor may produce different signaling responses and perhaps physiological outcomes. A classic example of ligand-directed selectivity at the MOR is the agonist morphine, which, at the molecular level, fully activates G-protein signaling but weakly internalizes receptors in vivo (in animal experiments) and in vitro. In contrast, the potent and non-selective opioid agonist etorphine, at the molecular level, internalizes receptors robustly and rapidly in animal experiments and in vitro. These early observations of different receptor internalization responses to two opioid agonists suggested distinct agonist-directed regulation of MORs, which may explain differences in observed physiological responses of these two agonists. Besides G-protein regulation, MORs are also regulated by phosphorylation through kinase activity like GRKs, JNKs, and PKCs and through the recruitment of β-arrestins, which can also drive additional receptor-mediated signaling events at internal membrane compartments.

Following the discovery that β-arrestin knockout (KO) animals treated with morphine showed enhanced antinociception with decreased respiratory depression and constipation,

### Table 1. Genetically modified mice available to study the mu opioid receptor (MOR) or MOR-expressing cells discussed in this review.

| Mouse line | Mouse line | Findings | Refs |
|------------|------------|----------|------|
| **Detecting MOR expression and localization in tissues and in vivo** | | | |
| Knock-in MOR reporter mice | MOR with a C-terminal mCherry fusion | MOR expression was visualized at the brain, neuron, and subcellular level with an enriched expression in medial habenula | 54,55 |
| | MOR with a C-terminal Venus fusion | Different MOR internalization profiles were visualized depending on MOR agonists | 45 |
| **Manipulating MOR-expressing neurons** | | | |
| Knock-in MOR-Cre mice | MOR-Cre mouse with a T2A cleavable peptide-Cre recombinase | Fine mapping of MOR striatal projection neurons in the patch compartment of the striatum | 56 |
| | MOR-Cre mouse with a T2A cleavable peptide and tamoxifen-inducible Cre recombinase | n/a | 57 |
| | MOR-Cre with a T2A cleavable peptide and Cre recombinase fused to an enhanced green fluorescent protein | Activation of ventral tegmental area-MOR neurons produced a strong place aversion | 58 |
the “arrestin hypothesis” or the idea that β-arrestin mediates adverse side effects of MOR activation further motivated the academic field and industry to design G-protein-biased MOR agonists or drugs that would activate β-arrestin less than the G-protein pathway (Figure 2)\textsuperscript{52}. The novel agonists that have emerged since, including TRV-130, commercially named OLINVYK\textsuperscript{59}, PZM21\textsuperscript{60}, and SR17018\textsuperscript{61}, were proposed to be potent G-protein activators with high analgesic effect, low β-arrestin recruitment, and low respiratory depression and thus greater therapeutic windows.

Since these new G-protein-biased ligands have been made available to the scientific community, additional studies have revealed results that should also be considered when designing G-protein-biased MOR drugs. For example, in one report, PZM21 has been shown to produce respiratory depression to a similar extent as morphine\textsuperscript{62}; however, in another study, minimal respiratory depression was observed with much higher concentrations of PZM21 in mice\textsuperscript{63}, and the adverse condition of hyperalgesia has been observed at low non-antinociceptive doses of PZM21 in rats\textsuperscript{64}. TRV-130 was found to retain side effects, including constipation in mice\textsuperscript{65} and reward in rats\textsuperscript{66}.

Finally, in agreement with the original paper, SR17018\textsuperscript{61} has been shown to produce minimal respiratory depression in comparison to other MOR agonists, albeit with a limited dosage window because of the use of a less-soluble salt version than the original SR17018 and using different methods to measure and quantify respiratory depression in mice\textsuperscript{67}.

Additionally, while bias toward the G-protein pathway has been the sought-after hallmark of a safer MOR ligand, the contribution of the β-arrestin pathway to respiratory depression remains unclear\textsuperscript{68}/\textsuperscript{69}. Morphine still induces respiratory depression in mice which have MORs that are phosphorylation deficient and thus do not recruit β-arrestins\textsuperscript{70}. Moreover, a recent study shows that β-arrestin KO mice do exhibit morphine-induced respiratory depression and constipation\textsuperscript{71}, challenging the role of the “arrestin hypothesis” in MOR adverse effects.

Nevertheless, TRV-130 (OLINVYK\textsuperscript{59}) has gone on to clinical trials in Asia and Europe and has recently been approved by the FDA in the U.S. as an intravenous drug for the management of moderate-to-severe acute pain\textsuperscript{72}. In clinical trials, OLINVYK\textsuperscript{59} provided potent analgesia that was superior to that observed in patients treated with placebo and was accompanied by a lower occurrence of adverse events, such as respiratory and gastrointestinal events, compared to morphine\textsuperscript{73}/\textsuperscript{74}. These findings suggest that while the contribution of β-arrestin signaling to respiratory depression remains a subject of investigation, G-protein-biased agonists which exhibit lower respiratory depression than balanced opioid drugs do hold promise for safer pain management with opioids.

In a recent paper, the concept of biased agonism was challenged as the reason for the observed improved safety profiles of PZM21, TRV-130, and SR17018. The authors\textsuperscript{75} suggest an alternative mechanism of how low intrinsic efficacy of these compounds can distort the interpretation of highly amplified G-protein activity assays and can account for confounding factors that impact the operational model\textsuperscript{76} used to calculate bias between G-protein and arrestin pathways. Indeed, overexpressed receptor expression systems have shown that MOR agonist efficacy in signaling varies widely across drugs but correlates with receptor internalization\textsuperscript{77}. The authors show that in transiently transfected cells, comparable assessment of compounds across signaling pathways accounting for variation in kinetics, temporal location of receptors, cell systems, receptor reserve, amplified detection methods, and inclusion of therapeutic window calculation in mice find PZM21, TRV-130, and SR17018 to be low intrinsic efficacy compounds rather than G-protein biased\textsuperscript{78}. Importantly, depending on the analysis methodology, these data may also support the fact that PZM21, TRV-130, and SR17018 are G-protein-biased agonists, as suggested in a recent re-analysis of Gillis et al.’s work\textsuperscript{59}. These studies demonstrate how biased agonism at MORs is still an emerging area and that MOR signaling activities are a hotly discussed area of investigation.

Intriguingly, G-protein bias has also been observed with endogenous opioid ligands. Most recently, functional selectivity was examined by GTPγS and β-arrestin recruitment for 22 endogenous opioid peptides\textsuperscript{79}. In addition to measuring bias, the authors demonstrated that binding activity of classically distinct peptides (enkephalins, endorphins, and dynorphins) was shown at all three opioid receptors, thus suggesting that, evolutionarily, opioid receptors are designed to bind multiple ligands that direct distinct signaling and physiological outcomes. Furthermore, it is important to assess drug activities at native MORs in neurons. Recently, MOR agonist-directed receptor redistribution in native neurons was shown to correlate well with overexpressed receptor internalization in HEK-293 cells, suggesting that MOR agonist activities can be evaluated in native receptor conditions by measuring receptor trafficking\textsuperscript{80}.

Remarkably, in three completely independent studies, a partial MOR agonist, buprenorphine, performs like the ultimate opioid, with rapid and potent G-protein activity, negligible

![Figure 2. Biased agonist-induced signaling. Agonists that efficiently induce opioid receptor activation of both G-protein and β-arrestin are thought of as balanced or unbiased ligands. If either G-protein or β-arrestin effects are more efficiently activated by a ligand, they are known as biased agonists66.](image-url)
arrestin recruitment or receptor internalization, rapid and sustained antinociception in hotplate test, and low respiratory depression effects. Buprenorphine thus appears to be effective in experimental nociceptive assays and is a current mainstay treatment for opioid use disorder. Some caveats exist, though; buprenorphine may be difficult to prescribe for pain owing to its restricted regulation as a schedule III drug in the U.S., complex pharmacology including off-target effects at other opioid receptors such as antagonism at Kappa, and its delicate dosing and limited bioavailability.

Collectively, the ideal opioid would have a wide therapeutic window and be a potent analgesic, with limited euphoria and respiratory depression. Thus far, opioids such as buprenorphine, PZM21, TRV-130, and SR17018 at the system level are antinociceptive and have lower respiratory depression in animal studies; at the molecular level, they also have in common miniscule loss of receptor from the cell surface, weak GRK recruitment, weak arrestin recruitment, weak receptor translocation to endosomes, and similar phosphorylation barcodes detected by western blotting. Designing new opioids which satisfy all these criteria will hopefully yield good candidates for clinical trials soon.

**Visualizing opioid receptors in vivo using KI animals**

In the last 15 years, since the creation of fluorescent opioid receptor KI mice, MOR-KI mice have become a valuable tool in deciphering the role of these receptors at the circuit and cellular level. Here, we focus on the MOR and how knowledge acquired with MOR-KI may serve to improve our understanding of opioid analgesia. On the anatomical level, mapping of MORs using MOR-mCherry mice has revealed prominent receptor populations in the diencephalic conduction system, including the striatum, septum, habenula, and interpeduncular nucleus. The particularly unique pattern of MOR in the medial habenula, a dense brain area important for aversion and inhibitory control, has raised questions about the role of MORs in the medial habenula and given insight into opioid analgesia circuitry. Additionally, extensive mapping of MOR-mCherry mice crossed with DOR-eGFP mice revealed the existence of colocalized and immunoprecipitated complexes of MOR and DOR receptors, called receptor heteromer populations. The DOR-eGFP/MOR-mCherry animals have become a critical tool (for review, see) for investigations of these potential therapeutic targets, MOR-DOR heteromers, in antinociception in vitro and in vivo. Furthermore, MOR-mCherry mice alone have been used to dispute and dislodge glial cell populations, such as the lack of MOR expression in spinal microglia or presence of MOR in astrocytes of the hippocampus. More recently, MOR-Venus mice were created employing the highly photo- and thermo-stable fluorescent protein Venus, adding resonance energy transfer capabilities. Mapping of MOR-Venus signals in whole mouse brain revealed a MOR expression profile in agreement with MOR-mCherry anatomy, showing how robust the fluorescent receptor KI mouse approach is. MOR-Venus mice were used to identify agonist-directed receptor trafficking profiles for biased and classic MOR agonists in neurons, which correlated to receptor activities in overexpression systems, supporting the relevancy of biased MOR agonists to physiology. Additionally, KI mice can be used to probe in vivo protein–protein interactions, as the fluorescent fusion proteins or epitope tags are amenable to proteomic approaches. This has recently been shown for the N-terminally tagged delta opioid receptor, which if extended to MORs would help improve our understanding of the proteins interacting directly with MOR, called the MOR interactome. Collectively, these KI genetic approaches allow basic scientists to trace endogenous MOR activities using fluorescence and immunoreactive methods. Caveats to this method include the possibility that altering the endogenous protein by addition of a short sequence in the case of an epitope tag or by addition of a fluorescent protein could impact the behavior of the receptor and its interactions with proteins and ligands. However, to date, this is the best tool that we have to directly observe endogenous receptor activities at the molecular level. Thus, fluorescent receptor KI animals are excellent tools to investigate novel opioid effects at endogenous receptors on cellular and whole animal levels.

**Distinguishing agonist effects by probing MOR conformational states**

Direct observation of drug-induced receptor activation in cells has not been possible until recently. New advances in structural biology have led to the generation of such probes that can be employed to distinguish receptor conformational states in transfected cell culture systems. Two types of probes derived from structural studies that are being used to study opioid receptor proximal activities are nanobodies, also known as single-domain antibodies, and mini-G proteins, which are composed of the Ras-like domain of G-protein α subunit and Nb33, a nanobody that binds selectively to a specific antigen. The first demonstrated was a MOR and delta receptor proximal conformational biosensor in an elegant study discerning peptide from non-peptide opioid agonist-induced receptor activities in cultured cells (MOR transfected HEK-293 and rat embryonic striatal neurons).

Additionally, this opioid biosensor offers the ability to study receptor proximal events, which can help to distinguish direct ligand-induced receptor activities from indirect downstream signaling or examine agonist-induced intrinsic efficacy. In recent research using these tools, the authors demonstrated how Nb33 and mini-G fluorescent engineered probes can detect distinct opioid receptor states induced by ligands coupling to the receptor. For example, in a TIRF microscopy assay in HEK-293 cells, etorphine recruited both mini-Gsi and Nb33 equally, whereas DAMGO, morphine, and PZM21 had higher potency for mini-Gsi, with the latter two having higher efficacy for mini-Gsi over Nb33. Intriguingly, the semi-synthetic natural product mitragynine pseudoindoxyl recruited mini-Gsi but not Nb33, supporting the idea that, in controlled cell culture studies, distinct ligands induce selective conformational changes of receptors that may impact receptor signaling and regulation. This is an active area of investigation, and the implications of ligand-induced distinct conformational changes
on MOR activities have yet to be directly assessed in vivo and ultimately in controlled clinical trials.

Enabling the study of endogenous MORs has also been helped by recent advances in traceless affinity labeling that have now made it possible for ligand-directed irreversible fluorescent tagging of endogenous MOR in rat and mouse brain slices that will allow for the tracing of endogenous MOR activities in vivo in response to biased agonists and could be applied to primary cultured neuron studies. For now, these studies are mainly done in cultured cells or slices, and in the future it will be important to determine if these MOR activities are also seen in post-mortem or immunopuripotent stem cell-derived human neurons.

Cellular contributions of time and space to MOR signaling

MOR signaling from the plasma membrane has been the prevailing view as the site of its action. However, a growing number of GPCRs have been shown to signal from subcellular compartments, including endosomes and Golgi. Employing advanced microscopy techniques, Stoebner and co-authors showed that in mammalian cells and striatal neurons, peptide opioids differ from non-peptide opioids in that the former activate receptors first at the plasma membrane and then at endosomes whereas the latter activate opioid receptors at a third location, Golgi outposts. These findings may help to explain distinct opioid-induced cellular effects, in particular, by identifying how synthetic opioid drugs like morphine, which signals at Golgi, contribute to distinct signaling responses compared to endogenous opioids. In the clinic, peptides are not prescribed owing to their low activity after systemic administration. However, their potential for drug development has been reviewed elsewhere, and these studies highlight the need to take the location of signaling receptors into account when designing new drugs.

MORs are also found on axons, and the contribution of presynaptic MORs to MOR cellular biology has not been well understood. Recent work in rat primary neurons using super resolution microscopy and MORs fused with a fluorescent reporter emitting fluorescence in function of the acidity of the environment (pH-sensitive GFP-tagged MORs) demonstrated that MORs are laterally mobile on the axonal surface and locally recycle separately from the synaptic vesicle cycle, which may have considerable impact on understanding MOR agonist-induced presynaptic inhibition and neuromodulation. How distinct opioid nonpeptide or peptide agonists impact MORs in axons and various neuronal subcellular locations remains to be seen. Perhaps these questions will be addressed using emerging new tools and techniques. For example, a recent proteomic approach known as APEX combines proximity-based biotinylation with mass spectrometry to allow for quantitative, time-resolved measurement of GPCR agonist response in living cells. When combined with spatial references, proteins that delineate precise cellular compartments, this technique allows for the detection of GPCR–protein interaction networks resolved in time and space. If adapted to living neurons, this approach could help to distinguish local signaling molecular events at presynaptic receptors from postsynaptic receptors and potentially identify more precise therapeutic targets. Remarkably, a recent study on the delta opioid receptor demonstrates that activating endosome-localized delta receptors of nociceptors using innovative nanoparticle-encapsulated agonists cause a long-lasting inhibition of neuronal excitability, suggesting that spatiotemporal organization of receptor activities impacts opioid physiology. These studies and others demonstrate that spatial location of opioid receptor signaling is a rapidly developing area of investigation and an important factor in understanding opioid mechanisms of action which could yield new therapeutics that target more precise receptor populations.

Manipulating MOR-expressing neurons to identify function(s) of opioid circuitry using KI animals

Combining Cre technology (genetic modification using Cre recombinase in animals) with chemogenetics (genetically modified proteins engineered to be activated with a small molecule) or optogenetics (genetic manipulation of specific neuronal populations by using light to control neurons expressing light-sensitive ion channels) allows for the mapping or manipulation of select neurons or to even record neuronal activity using fluorescent calcium indicators (genetically engineered calcium biosensors) in Cre-positive neurons. New genetic tools were recently designed to manipulate neurons expressing opioid peptides or opioid receptors. Similar tools have already been used to determine distinct novel functions of neurons expressing opioid peptides. For example, it was demonstrated that preprodynorphin (Pdyn)-expressing neurons in the nucleus accumbens shell may drive opposite behavior (aversion or preference) depending on the localization of these neurons in the shell subregion (ventral versus dorsal). Furthermore, animals that express a Cre-recombinase under proopiomelanocortin or proenkephalin promoters were generated and anatomically characterized and will be interesting to use in pain- or addiction-related studies to determine the adaptations occurring in opioid circuitries. Tools to target opioid receptor neurons are also now available. KOR-Cre was the first KI mouse generated and characterized, in which opioid receptor-positive neurons express Cre-recombinase.

Recently, three independent laboratories designed, generated, and characterized in parallel three novel genetic tools, allowing the targeting and manipulation of specific neurons expressing MOR in vivo. Márton et al. generated a MOR-Cre mouse strain by inserting a Cre recombinase with a peptide that is autocleavable, allowing the separation of the MOR and Cre proteins, called T2A cleavable peptide-Cre recombinase, that was inserted into the fifth exon of the gene coding for MOR. This MOR-Cre mouse strain was crucial to map MOR striatal projection neurons in the patch compartment of the striatum. Okunomiya et al. designed and characterized an inducible MOR-Cre KI mouse strain, in which the stop codon, which signals the termination of the translation process of the
Oprml gene, was replaced by a DNA fragment encoding a T2A cleavable peptide and an inducible Cre recombinase. The inducible Cre recombinase is made by the fusion of a mutated ligand-binding domain of the estrogen receptor to the Cre recombinase variant, which made this inducible Cre activated only after delivery of tamoxifen. Finally, Bailly et al. generated a MOR-Cre mouse strain by inserting a T2A cleavable peptide and Cre recombinase fused to a fluorescent reporter protein (enhanced GFP), allowing the detection of the Cre and thus the MOR neurons, in the fourth exon of the Oprml gene. This mouse strain was characterized, and MOR signaling was intact, as demonstrated by typical morphine-induced antinociception, sensitization, and the classic morphine-induced hyperlocomotion in mice. Bailly and co-authors used the MOR-Cre animals to activate ventral tegmental area-MOR neurons by optogenetics, and, as it was anticipated from literature that has shown how opioids inhibit these neurons and produce reward, the opposite action by optogenetic activation of these neurons produced a strong aversion. These mouse lines will be critical for future investigation into the functions of opioid-responsive neurons in antinociception and side effects such as respiratory depression to determine how subsets of MOR neurons can operate in precise circuits to contribute to opioid physiology and adaptations. For example, MOR-Cre mice will help to delineate the role of MOR neurons of the pre-Bötzinger complex, as it was shown recently, using local deletion of the MOR in mice, that opioid activation of MOR neurons of the pre-Bötzinger complex seems to have the strongest impact on respiratory depression. Another application of these MOR-Cre lines may be to study the activity of MOR-expressing neurons using calcium imaging. For example, time-lapse in vivo calcium imaging was used to identify a neural ensemble in the basolateral amygdala that mediates unpleasantness in an animal model of persistent nociceptive stimulation, and targeting these neurons may reduce nociceptive responses without increasing reward. Furthermore, similar studies using MOR-Cre mice may help to identify opioid-responsive circuitry implicated in unpleasantness associated with nociceptive stimulation. Finally, it will be crucial in the future to engineer safe viral-mediated therapeutics to target specific neuronal populations in humans.

The creation of these MOR-Cre strains will allow the scientific community to map and chemogenetically or optogenetically manipulate or record neuronal activity of opioid-responsive neurons to improve understanding of opioid-responsive neuronal networks and their adaptations and may thus identify new concepts relevant for opioid analgesia. Altogether, these new Cre lines are opening doors for both mapping and functional studies of opioid receptor/-peptide-expressing neurons and may be crucial to understand opioid analgesia.

Effects of analgesic opioids on whole-brain connectivity and activity using MRI

Different types of environmental stimuli, such as pain or repeated opioid use, cause neuroadaptations. These adaptations can impact whole-brain function. A method to evaluate brain connectivity and activities at the whole scale level with translational potential is MRI. The complexity of human brain networks starts to be transposable in rodents, as similar resting state networks are found in rodents and humans, which allows for parallel non-invasive longitudinal experiments in living humans and animals. Recently, pharmacological MRI has emerged as a method to map brain activation following acute effects of opioid analgesics in humans and rodents. Pharmacological MRI is a highly powerful method to understand brain responses to drugs and has been developed in rodents and humans. In opioid-naive individuals, a morphine or buprenorphine challenge altered blood-oxygen-level-dependent (BOLD) signals in the periaqueductal grey. Additionally, in humans, oxycodone reduced and disrupted functional connectivity between anterior cingulate cortex and insula or dorsal striatum centers belonging to the pain and reward centers. Nevertheless, the overall impact of opioid exposure on brain network activities remains poorly understood.

The MOR-mediated adaptations contributing to these whole-brain effects have started to be investigated, and animal MRI may be the most appropriate tool to reach this goal, as animals with MOR (wild-type [WT]) or without (KO) are available. First, it was demonstrated that the deletion of MOR is enough to alter resting-state functional connectivity. Interestingly, the strongest modification occurred in the reward/aversion circuitry, including regions important for analgesia, such as the periaqueductal gray. Secondly, pharmacological MRI analysis enabled the determination of oxycodone patterns of brain activation and oxycodone effects on whole-brain functional connectivity.

In the latter study, oxycodone effect was assessed in WT and MOR-KO animals to extract MOR-dependent whole-brain functional connectivity signatures using functional MRI (fMRI). Importantly, almost no effect of oxycodone was found in MOR-KO mice, indicating that the oxycodone whole-brain functional connectivity signatures are MOR mediated. Using a data-driven analysis (independent component analysis), it was demonstrated that oxycodone produced a reduction of functional connectivity across 71 components including the isocortex, nucleus accumbens, and periaqueductal gray, brain regions important for the antinociceptive effects of opioids. Furthermore, focused and hypothesis-oriented analysis (seed-to-seed) presented highest functional connectivity reduction between the periaqueductal gray and nucleus accumbens, showing that oxycodone impacts brain activity in reward and aversion/pain networks.

Since rodent fMRI is still emerging, more effort should be put into applying resting-state fMRI to understand opioid analgesia. fMRI studies on the opioid system will be necessary to study the effect of opioid circuitry on whole-brain communication and to determine how distinct opioids act on reward, respiratory depression, or pain networks, and if distinct opioids are acting differently on these networks. The hope will be to find an opioid analgesic targeting only the pain networks without affecting centers such as hubs implicated in reward or respiration. This may be achieved using fMRI in rodents by first identifying the brain networks activated by classical opioids like...
morphine and then comparing to novel opioid drugs that produce limited unwanted effects on reward and respiration. A comparison of opioid drugs may reveal a signature with which future opioid drug design would aim to reach. Furthermore, rodent MRI combined with optogenetic13,15,16 or chemogenetic17,18 tools can identify the impact of neuronal populations on whole-brain activity. These methods may eventually allow for the discovery of the link between microcircuit opioid activity and the brain network at the mesoscale level. For example, chemogenetic manipulations and fMRI were combined recently to map serotonergic transmission, and the stimulation of serotonergic activity induced particular activation of brain regions covering cortico-hippocampal and ventro-striatal areas important for depressive-like behaviors.19,20 Further studies, to determine the effect of local manipulation of MOR circuitry on whole-brain communication using MOR-Cre animals, may help to characterize opioid-responsive circuits with the goal to improve opioid analogs. Altogether, these recent studies demonstrate that high-resolution fMRI is possible in rodents combined with diverse genetic tools and holds potential for translation as similar longitudinal studies will be possible in humans and rodents.

Conclusion

Altogether, recent advances in the characterization of MORs will help to determine future strategies to develop a MOR agonist that alleviates pain and has fewer side effects. The new methodologies discussed here represent a selection of studies employing exciting new tools being developed to study MORs, all the way from subcellular mechanisms to mesoscale network responses. These studies will enhance our knowledge on opioid analgesia and physiology, guide future research, and innovate opioid pharmacology.

Acknowledgements

We thank Dr. Brigitte Kieffer (INSERM, U1114, France) for critical reading of the manuscript. Figures were created with BioRender (biorender.com).
Hyperlalgesic Priming in the Rat. Neuroscience. 2018; 394: 60–71. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

65. Altarri AA, David B, Muchalaa KH, et al.: Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. J Psychopharmacol. 2017; 31(6): 730–9. PubMed Abstract | Publisher Full Text | Free Full Text

66. Austin Zamarripa C, Edwards SR, Qureshi HN, et al.: The G-protein biased mu opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats. Drug Alcohol Depend. 2018; 182: 158–62. PubMed Abstract | Publisher Full Text | Free Full Text

67. Montandon G, Ren J, Victoria NC, et al.: G-protein-gated Inwardly Rectifying Potassium Channels Modulate Respiratory Depression by Opioids. Anesthesiology. 2016; 124(3): 641–50. PubMed Abstract | Publisher Full Text | Free Full Text

68. Conibear AE, Kelly E: A Biased View of μ-Opioid Receptors? Mol Pharmacol. 2019; 96(5): 542–9. PubMed Abstract | Publisher Full Text | Free Full Text

69. Kliever A, Schmidel F, Staraili S, et al.: Phosphorylation-deficient G-protein-biased μ- opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nat Commun. 2019; 10(1): 367. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

70. Kliever A, Gillis A, Hill R, et al.: Morphine-induced respiratory depression is independent of δ-presepsin signaling. Br J Pharmacol. 2020; 177(13): 2923–31. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

71. Singla NK, Skobieranda F, Soergel DG, et al.: APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty. Pain Pract. 2019; 19(7): 715–31. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

72. Dan TJ, Wise L: Oliceridine, a G protein-selective ligand at the μ-opioid receptor, for the management of moderate to severe acute pain. Drugs Today (Barc). 2020; 56(4): 269–86. PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation

73. Ayad S, Demtrick MA, Burt DA, et al.: Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain. Clin Drug Invest. 2020; 40(8): 755–64. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

74. Back JW, Left P: Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci. 1983; 220(119): 141–62. PubMed Abstract | Publisher Full Text | Free Full Text

75. McPherson J, Rivero G, Baptist M, et al.: μ-opioid receptors: Correlation of agonist efficacy for signaling with ability to activate internalization. Mol Pharmacol. 2015; 87(4): 756–66. PubMed Abstract | Publisher Full Text | Free Full Text

76. Stahl EL, Bohn LM: Re-evaluating how low intrinsic efficacy and apparent bias for G protein activation relates to the improved side effect profiles of new opioid agonists. bioRxiv. 2020; 2020.11.19.390018. Publisher Full Text

77. Gomes I, Siera S, Lueptow L, et al.: Biased signaling by endogenous opioid peptides. Proc Natl Acad Sci U S A. 2020; 117(21): 11620–8. PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation

78. Ehrlch AT, Darco E: Recommending buprenorphine for pain management. Pain Manage. 2019; 9(1): 13–6. PubMed Abstract | Publisher Full Text | Free Full Text

79. Johnson RE, Fudala PJ, Payne R: Buprenorphine: Considerations for pain management. J Pain Symptom Manage. 2005; 29(3): 297–326. PubMed Abstract | Publisher Full Text | Free Full Text

80. Kuyzer J, Wenthur CJ: Classics in Chemical Neuroscience: Buprenorphine. ACS Chem Neurosci. 2020; 11(10): 1385–99. PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation

81. Ayer R, Gulati A, Gungor S, et al.: Treatment of Chronic Pain With Various Buprenorphine Formulations: A Systematic Review of Clinical Studies. Anesth Analg. 2018; 127(2): 529–38. PubMed Abstract | Publisher Full Text

82. Scherrer G, Trypen-Töth P, Filillo D, et al.: Knockin mice expressing fluorescent delta-opsin receptors uncover G protein-coupled receptor dynamics in vivo. Proc Natl Acad Sci U S A. 2006; 103(23): 9691–6. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

83. Maduna T, Autour E, Dembélé D, et al.: Microglia Express Mu Opioid Receptor: Insights From Transcriptomics and Fluorescent Reporter Mice. Front Psychiatry. 2018; 9: 726. PubMed Abstract | Publisher Full Text | Free Full Text

84. Nam NH, Han KS, Lee J, et al.: Expression of μ-Opioid Receptor in CA1 Hippocampal Astrocytes. Exp Neurol. 2018; 272(2): 120–8. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

85. Corder G, Tawfik VL, Wang D, et al.: Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia. Nat Med. 2017; 23(2): 164–73. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

86. Daroz E, Koeble P, Del Boca C, et al.: RSK2 signaling in brain habena contributes to place avoidance learning. Learn Mem. 2011; 18(5): 574–8. PubMed Abstract | Publisher Full Text | Free Full Text

87. Kobayashi Y, Sano Y, Yannori E, et al.: Genetic dissection of medial habenula-interpeduncular nucleus pathway function in mice. Front Behav Neurosci. 2013; 7: 17. PubMed Abstract | Publisher Full Text | Free Full Text

88. Obou Y, Darzi A, Pietrajaš K, et al.: Control of aversion by glycine-gated GluN1/GluN3A NMDA receptors in the adult mediod habenula. Science. 2019; 368(6462): 250–4. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

89. Bools LJ, Ben Hamida S, Baillé J, et al.: Mu opioid receptors in the medial habena contribute to naloxone aversion. Neuropsychopharmacology. 2020; 45(2): 247–55. PubMed Abstract | Publisher Full Text | Free Full Text

90. Daroz E, Befort K, Koeble P, et al.: RSK2 signaling in medial habenula contributes to acute morphine analgesia. Neuropsychopharmacology. 2012; 37(5): 1288–96. PubMed Abstract | Publisher Full Text | Free Full Text

91. Ugur M, Derouich L, Massotte D: Heteromerization Modulates μ Opioid Receptor Functional Properties in vivo. Front Pharmacol. 2018; 9: 1240. PubMed Abstract | Publisher Full Text | Free Full Text

92. Fujita W, Gomes I, Devi LA: Heteromers of μ-μ opioid receptors: New pharmacology and novel therapeutic possibilities. Br J Pharmacol. 2015; 172(2): 375–87. PubMed Abstract | Publisher Full Text | Free Full Text

93. Wang D, Tawfik VL, Corder G, et al.: Functional Divergence of Delta and Mu Opioid Receptor Organization in CNS Pain Circuits. Neuron. 2018; 98(1): 90–108.e5. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

94. DegrangeMaison J, Abdallah K, Blais V, et al.: in vivo mapping of a GPCR interactome using knockin mice. Proc Natl Acad Sci U S A. 2020; 117(23): 13155–16. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

95. Huang W, Manglik A, Venkatakrishnan AJ, et al.: Structural insights into μ-opioid receptor activation. Nature. 2015; 524(7560): 315–21. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

96. Koehl A, Hu H, Maeda S, et al.: Structure of the μ-opioid receptor-Gi protein complex. Nature. 2018; 558(7711): 547–52. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

97. Nehmé R, Carpenter B, Singhal A, et al.: Mini-G proteins: Novel tools for studying GPCRs in their active conformation. PLoS One. 2017; 12(4): e0175642. PubMed Abstract | Publisher Full Text | Free Full Text

98. Wang G, Okashah N, Inoue A, et al.: Mini G protein probes for active G protein-coupled receptors (GPCRs) in live cells. J Biol Chem. 2018; 293(19): 7466–73. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

99. Stoeger M, Julte D, Lobinger BT, et al.: A Genetically Encoded Biosensor Reveals Location Bias of Opioid Drug Action. Neuron. 2018; 98(3): 563–576.e5. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

100. Stoeger M, Julte D, Li J, et al.: Agonist-selective recruitment of engineered protein probes and of GRK2 by opioid receptors in living cells. Elife. 2020; 9:e54208. PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

101. Varádi A, Marrone GF, Palmer TC, et al.: Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analogues with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arenergic-2. J Med Chem. 2016; 59(18):
102. Arttamangkul S, Plazeck A, Platt EJ, et al.: Visualizing endogenous opioid receptors in living neurons using ligand-directed chemistry. Elife. 2019; 8: e49319.

103. Thomsen ARB, Poullou B, Cahill TJ, et al.: GPCR-G Protein-β-Arrestin Super-Complex Mediates Sustained G Protein Signaling. Cell. 2016; 166(4): 907–19.

104. Iannejad R, Tomshie JC, Tomshie JR, et al.: Conformational biosensors reveal GPCR signaling from endosomes. Nature. 2013; 495(7442): 534–8.

106. Endomorphin-2. PubMed Abstract | Publisher Full Text | Free Full Text

108. Complex Mediates Sustained G Protein Signaling. PubMed Abstract | Publisher Full Text | Free Full Text

113. Olson KM, Lei W, Keresztes A, et al.: Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain. Yale J Biol Med. 2017; 90(1): 97–110.

115. Jullie D, Stobber M, Sibarta JB, et al.: A Discrete Presynaptic Vesicle Cycle for Neuromodulator Receptors. Neuron. 2020; 106(4): 663-677.e8.

116. de Marco R, Janecka A: Strategies to Improve Bioavailability and In Vivo Efficacy of the Endogenous Opioid Peptides Endorphin-1 and Endorphin-2. Curr Top Med Chem. 2015; 14(12): 141–55.

118. de Marco R, Janecka A: Strategies to Improve Bioavailability and In Vivo Efficacy of the Endogenous Opioid Peptides Endorphin-1 and Endorphin-2. Curr Top Med Chem. 2015; 14(12): 141–55.

120. Harris JA, Hirokawa KE, Sorensen SA, et al.: Anatomical characterization of Cre driver mice for neural circuit mapping and manipulation. Front Neural Circuits. 2014; 8: 76.

122. Bachmestyk I, Wei XP, Kish E, et al.: Opioids depress breathing through two small brainstem sites, eLife. 2020; 9: e52694.

124. Carder G, Ahanonu B, Greene BF, et al.: An amygdalar neural ensemble that encodes the unpleasantness of pain. Science. 2019; 363(6424): 276–81.

125. Lindemann L, Porter RH, Scharl SH, et al.: Pharmacology of bhasimalgurin (RM3497523, RG7096), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. J Pharmacol Exp Ther. 2015; 353(1): 213–33.

128. Bruns A, Künnecke B, Risterucci C, et al.: Validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological MRI in rats. Magn Reson Med. 2009; 61(6): 1451–8.

130. Moore K, Madularu D, Iriah S, et al.: A robust experimental protocol for pharmacological MRI in rats and mice. J Neurosci Methods. 2012; 204(1): 9–18.

132. Corder G, Ahanonu B, Greene BF, et al.: An amygdalar neural ensemble that encodes the unpleasantness of pain. Science. 2019; 363(6424): 276–81.

134. de Marco R, Janecka A: Strategies to Improve Bioavailability and In Vivo Efficacy of the Endogenous Opioid Peptides Endorphin-1 and Endorphin-2. Curr Top Med Chem. 2015; 14(12): 141–55.

136. Zarefias C, Patsalos PN, et al.: Pharmacological fMRI in rats and mice. Front Neurosci. 2015; 9: 220.

138. Moore K, Madularu D, Iriah S, et al.: A robust experimental protocol for pharmacological MRI in rats and mice. J Neurosci Methods. 2012; 204(1): 9–18.

140. Martone ME, et al.: Anatomical characterization of Cre driver mice for neural circuit mapping and manipulation. Front Neural Circuits. 2014; 8: 76.

142. Bruns A, Künnecke B, Risterucci C, et al.: Validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological MRI in rats. Magn Reson Med. 2009; 61(6): 1451–8.

144. Corder G, Ahanonu B, Greene BF, et al.: An amygdalar neural ensemble that encodes the unpleasantness of pain. Science. 2019; 363(6424): 276–81.

146. Bruns A, Künnecke B, Risterucci C, et al.: Validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological MRI in rats. Magn Reson Med. 2009; 61(6): 1451–8.

148. Martone ME, et al.: Anatomical characterization of Cre driver mice for neural circuit mapping and manipulation. Front Neural Circuits. 2014; 8: 76.

150. Martone ME, et al.: Anatomical characterization of Cre driver mice for neural circuit mapping and manipulation. Front Neural Circuits. 2014; 8: 76.

152. Seshadri S, Hoeppner DJ, Tajinda K: Delta opioid receptors is an endogenous mechanism and therapeutic target in brain disease in animal models. Genesis. 2016; 54(1): 29–37.

154. Bruns A, Künnecke B, Risterucci C, et al.: Validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological MRI in rats. Magn Reson Med. 2009; 61(6): 1451–8.

156. Martone ME, et al.: Anatomical characterization of Cre driver mice for neural circuit mapping and manipulation. Front Neural Circuits. 2014; 8: 76.

158. Martone ME, et al.: Anatomical characterization of Cre driver mice for neural circuit mapping and manipulation. Front Neural Circuits. 2014; 8: 76.